Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.

PURPOSE We evaluated whether men at risk for significant versus clinically insignificant prostate-specific antigen (PSA) failure after radical prostatectomy could be identified using information available at diagnosis. PATIENTS AND METHODS A prospective prostate cancer screening study that enrolled, diagnosed, and treated 1,011 men with radical prostatectomy at Barnes-Jewish Hospital (St Louis, MO) from January 1, 1989, to June 1, 2002, for localized prostate cancer formed the study cohort. Preoperative predictors of a postoperative PSA doubling time (DT) of less than 3 months and more than 12 months or no PSA failure were identified using logistic regression. RESULTS A preoperative PSA velocity more than 2.0 ng/mL/yr (P = .001) and biopsy Gleason score 7 (P = .006) or 8 to 10 (P = .003) were significantly associated with having a postoperative PSA DT less than 3 months. A PSA level less than 10 ng/mL (P = .005), a nonpalpable cancer (P = .001) with a Gleason score < or = 6 (P = .0002), and a preoperative PSA increase that did not exceed 0.5 ng/mL/yr (P = .03) were significantly associated with a postoperative PSA DT of at least 12 months or no PSA failure. Most men with these preoperative characteristics and a postoperative PSA DT of 12 months or more had a persistent postoperative PSA level of at least 0.2 ng/mL that did not exceed 0.25 ng/mL after a median follow-up of 3.6 years. CONCLUSION A postoperative PSA DT less than 3 months is associated with a preoperative PSA velocity more than 2.0 ng/mL/yr and high-grade disease. Select men with a postoperative PSA DT more than 12 months may not require salvage radiation therapy.

[1]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[2]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[3]  H. Kübler,et al.  Residual benign prostatic glands at the urethrovesical anastomosis after radical retropubic prostatectomy: prediction and impact on disease outcome. , 2004, European urology.

[4]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[5]  W. Catalona,et al.  Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. , 2004, The Journal of urology.

[6]  M. Cooperberg,et al.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Kattan,et al.  Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy , 2004 .

[8]  J Kurhanewicz,et al.  Magnetic resonance imaging and spectroscopic imaging of prostate cancer. , 2003, Cancer investigation.

[9]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[10]  A. D'Amico,et al.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Carroll,et al.  Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? , 2001, The Journal of urology.

[12]  M. Rubin,et al.  Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. , 2000, Urology.

[13]  A. Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[14]  P. Schellhammer,et al.  Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jeffrey J. Gaynor,et al.  On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .

[16]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[17]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[18]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[19]  Rupert G. Miller,et al.  Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.